Zai Lab/ZLAB

$18.14

1%
-
1D1W1MYTD1YMAX

About Zai Lab

Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.

Ticker

ZLAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Du Ying

Employees

2,175

Headquarters

Shanghai, China

Zai Lab Metrics

BasicAdvanced
$1.8B
Market cap
-
P/E ratio
-$3.50
EPS
1.16
Beta
-
Dividend rate
$1.8B
1.16424
$37.92
$13.48
636K
4.626
4.429
6.334
-31.41%
-38.44%
-36.81%
6.261
2.357
2.44
25.94%
18.15%
75.96%

What the Analysts think about Zai Lab

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
198.51% upside
High $66.00
Low $25.00
$18.14
Current price
$54.15
Average price target

Zai Lab Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.3% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$87M
32.37%
Net income
-$53M
-44.03%
Profit margin
-61.3%
-57.72%

Zai Lab Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 45.94%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.25
-$0.71
-$1.00
-$0.50
-
Expected
-$0.79
-$1.04
-$0.86
-$0.92
-$0.77
Surprise
58.43%
-32.01%
16.82%
-45.94%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for Zai Lab stock?

Zai Lab (ZLAB) has a market cap of $1.8B as of May 30, 2024.

What is the P/E ratio for Zai Lab stock?

The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of May 30, 2024.

Does Zai Lab stock pay dividends?

No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Zai Lab dividend payment date?

Zai Lab (ZLAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Zai Lab?

Zai Lab (ZLAB) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Zai Lab stock price target?

The target price for Zai Lab (ZLAB) stock is $54.15, which is 198.51% above the current price of $18.14. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Zai Lab stock

Buy or sell Zai Lab stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing